Fund shareholders of NOVABAY PHARMACEUTICALS INC
ISIN US66987P5089 · United States · LEI 549300D5U7PQPNEX8Q38
- Fund shareholders
- 5
- Of which ETFs
- 1 4 other funds
- Value held
- 801.9K $
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 272,157 | 405.5K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 130,744 | 188.3K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| iShares Core S&P Total U.S. Stock Market ETF iShares Trust | 56,515 | 84.2K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 47,860 | 68.9K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 38,159 | 54.9K $ | 0.00 % | as of Feb 28, 2026 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 0.00 % | as of Mar 31, 2026 ↗ |
| Fidelity Series Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| Fidelity Total Market Index Fund Fidelity Concord Street Trust | 0.00 % | as of Feb 28, 2026 ↗ |
| iShares Core S&P Total U.S. Stock Market ETF iShares Trust | 0.00 % | as of Mar 31, 2026 ↗ |
Institutional managers
21 managers declare this company to the SEC (Form 13F).
| Manager | Shares | Value | |
|---|---|---|---|
| BlackRock, Inc. | 423,343 | 630.8K $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 290,269 | 432.7K $ | as of Mar 31, 2026 |
| JANE STREET GROUP, LLC | 121,104 | 180.4K $ | as of Mar 31, 2026 |
| STATE STREET CORP | 117,154 | 174.6K $ | as of Mar 31, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | 82,795 | 123.4K $ | as of Mar 31, 2026 |
| NORTHERN TRUST CORP | 53,676 | 80K $ | as of Mar 31, 2026 |
| Qube Research & Technologies Ltd | 41,975 | 62.5K $ | as of Mar 31, 2026 |
| TWO SIGMA INVESTMENTS, LP | 24,795 | 36.9K $ | as of Mar 31, 2026 |
| State of Wyoming | 24,298 | 36.2K $ | as of Mar 31, 2026 |
| Schonfeld Strategic Advisors LLC | 14,604 | 21.8K $ | as of Mar 31, 2026 |
| Catalyst Funds Management Pty Ltd | 13,681 | 20.4K $ | as of Mar 31, 2026 |
| HRT FINANCIAL LP | 13,503 | 20 $ | as of Mar 31, 2026 |
| Tower Research Capital LLC (TRC) | 2,148 | 3.2K $ | as of Mar 31, 2026 |
| WELLS FARGO & COMPANY/MN | 950 | 1.4K $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 3 | 4 $ | as of Mar 31, 2026 |
| FMR LLC | 3 | 4 $ | as of Mar 31, 2026 |
| UBS Group AG | 3 | 4 $ | as of Mar 31, 2026 |
| Addison Advisors LLC | 1 | 2 $ | as of Mar 31, 2026 |
| JPMORGAN CHASE & CO | 1 | 1 $ | as of Mar 31, 2026 |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 1 | 1 $ | as of Mar 31, 2026 |
| NVWM, LLC | 1 | 1 $ | as of Mar 31, 2026 |
Declared shareholders of NOVABAY PHARMACEUTICALS INC
There are 4 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| R01 Fund LP and 3 others | 49.80 % | 37,523,338 | as of Jun 15, 2026 · SCHEDULE 13D |
| Framework Ventures IV L.P. and 4 others | 45.90 % | 32,690,366 | as of Jun 15, 2026 · SCHEDULE 13D |
| Tether Global Investments Fund, S.I.C.A.F., S.A. and 2 others | 9.99 % | 3,009,502 | as of May 17, 2026 · SCHEDULE 13G |
| Sky Frontier Foundation | 9.90 % | 3,009,502 | as of May 17, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Fund shareholders of NOVABAY PHARMACEUTICALS INC". https://titelia.com/en/stocks/novabay-pharmaceuticals-inc-US66987P5089